These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6821216)

  • 1. Inhibition of arterial PGI2 generation and platelet aggregation by aspirin in rabbits ex vivo.
    Basista M
    Pol J Pharmacol Pharm; 1982; 34(5-6):317-21. PubMed ID: 6821216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral aspirin dose on platelet aggregation and arterial prostacyclin synthesis: studies in humans and rabbits.
    Ellis EF; Jones PS; Wright KF; Richardson DW; Ellis CK
    Adv Prostaglandin Thromboxane Res; 1980; 6():313-5. PubMed ID: 6770601
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis.
    Srivastava R; Puri V; Srimal RC; Dhawan BN
    Arzneimittelforschung; 1986 Apr; 36(4):715-7. PubMed ID: 3521617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans and rabbits.
    Ellis EF; Wright KF; Jones PS; Richardson DW; Ellis CK
    J Cardiovasc Pharmacol; 1980; 2(4):387-97. PubMed ID: 6156337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment.
    Buchanan MR; Dejana E; Gent M; Mustard JF; Hirsch J
    J Clin Invest; 1981 Feb; 67(2):503-8. PubMed ID: 7007438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prostacyclin-sparing effect of indobufen vs. aspirin.
    De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
    Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic initial phase of platelet aggregation inhibition after oral aspirin.
    Walter E; Zimmermann R; Siess R; Staiger C; Weber E
    Artery; 1980; 8(5):501-6. PubMed ID: 7213053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet adhesion and mural platelet thrombus formation on aortic subendothelium of rats, rabbits, and guinea pigs correlate negatively with the vascular PGI2 production.
    Tschopp TB; Baumgartner HR
    J Lab Clin Med; 1981 Sep; 98(3):402-11. PubMed ID: 7021720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity ratio between antiprostacyclin and antiaggregating effects of acetylsalicylic acid, indometacin and ditazole.
    Caprino L; Togna G; Antonetti F; Borrelli F
    Arzneimittelforschung; 1980; 30(3):406-9. PubMed ID: 6104493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acetylsalicylic acid on human platelet function in vivo at salicylate steady state.
    Simrock R; Missalla A; Schwidtal P; Lischke V; Breddin HK
    Thromb Haemost; 1984 Apr; 51(2):269-71. PubMed ID: 6740559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs.
    Ohmuro S; Sasahara T; Taga F; Ohkubo H; Uchida H
    Arzneimittelforschung; 1992 Jan; 42(1):43-7. PubMed ID: 1586379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of prostacyclin production by vascular cells in in vitro and in vivo experimentals systems.
    Dejana E; Prosdocimi M; de Gaetano G
    Wien Klin Wochenschr; 1986 Apr; 98(7):206-8. PubMed ID: 3010579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K; Nishiyama H; Kikuchi S; Kondo K; Nakashima M
    Thromb Haemost; 1996 Nov; 76(5):799-806. PubMed ID: 8950793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.